Formulation, In-vitro Evaluations and Skin Irritation Study of Losartan Potassium Transdermal Patches Formulation of losartan transdermal patches
Iranian Journal of Pharmaceutical Sciences,
Vol. 6 No. 3 (2010),
1 July 2010
,
Page 163-170
https://doi.org/10.22037/ijps.v6.41267
Abstract
Losartan potassium is a well known orally active non-peptide angiotensin II receptor antagonist. Losartan potassium and its principle active metabolites block the vasoconstrictor and aldosterone secreting effect of angiotensin II by selectively blocking the binding of angiotensin II to AT1 receptors. The drug is reported to promote the decrease in ventricular hypertrophy, salt and water excretion and vascular smooth muscle relaxation. Present investigation was aimed at the formulation of transdermal therapeutic system of losartan potassium for effective control over hypertension since the drug shows considerable first pass metabolism when administered through oral route. Blends of hydrophobic and hydrophilic polymers like ethyl cellulose with polyvinyl pyrrolidone and ethyl cellulose with hydroxypropyl methyl cellulose were used in the formulation of the medicated films. Films were prepared using dibutyl phthalate as plasticizer with eighteen different combinations of these three polymers by solvent evaporation technique. Polyvinyl alcohol was used to prepare the backing membrane. Several physicochemical parameters like moisture content, moisture uptake, thickness, film folding endurance, tensile strength, skin irritation and surface morphology of the films were studied. For all the formulations, skin permeation of the loaded drug through albino mice skin was studied using Keshary-Chien diffusion cell. Formulations containing higher proportion of hydrophilic polymers blended with lower proportions of hydrophobic polymer were found less consistent in comparison to the patches comprised of higher proportion of hydrophobic polymer.
- Ethyl cellulose
- Hydroxypropyl methyl cellulose
- Losartan potassium
- Polyvinyl pyrrolidone
How to Cite
References
[2] Barry BW. Dermatological formulations, percutaneous absorption. New York: Marcel Dekker; 1987.
[3] Robinson JR, Lee VHL. Controlled drug delivery, fundamentals and applications. 2nd ed. New York: Marcel Dekker; 1987.
[4] Paudel KS, Nalluri BN, Hammell DC, Valiveti S, Kiptoo P, Hamad MO, Crooks PA, Stinchcomb AL. Transdermal delivery of naltrexone and its active metabolite 6-β-naltrexol in human skin in vitro and guinea pigs in vivo. J Pharm Sci 2005; 94: 1965-74.
[5] Dey BK, Nath LK, Bhowmik BB. Development and evaluation of propranolol hydrochloride transdermal patches by using hydrophilic and hydrophobic polymer. Indian J Pharm Educ Res 2007; 41: 388-93.
[6] Das MK, Bhattacharya A, Ghosal SK. Transdermal delivery of trazodone hydrochloride from acrylic films prepared from aqueous latex. Indian J Pharm Sci 2006; 68: 41-6.
[7] Murthy TEGK, Mallikarjuna P, Murali K. Design and development of piroxicam transdermal films. Pharma Rev 2004; 12: 145-7.
[8] Sumanta MK, Dube R, Suresh B. Transdermal drug delivery system of a haloperidol to overcome self-induced extrapyramidal syndrome. Drug Devlop Ind Pharm 2003; 29: 405-15.
[9] http:// www. cspscanada. Org
[10] Gattani SG, Gaud RS, Chaturvedi SC. Formulation and evaluation of transdermal films of chlorpheniramine maleate. Indian Drugs 2007; 44: 27-33.
[11] Bharkatia M, Nema RK, Gupta GD, Gaud RS. Designing and evaluation of propranolol hydrochloride transdermal patch. Pharma Rev 2005; 3: 113-6.
[12] Stoughton RB, Fritsch W. Influence of dimethyl sulfoxide on human percutaneous absorption. Drug Dev Ind Pharm 2003; 29: 405-7.
[13] Gupta PS, Jain SK. Effective and controlled transdermal delivery of metoprolol tratarate. Indian J Pharm Sci 2005; 67: 346-50.
[14] Kulkarni RV, Mutalik S, Hiremath D. Effect of plasticizers on the permeability and mechanical properties of eudragit films for transdermal application. Indian J Pharm Sci 2002; 64: 28-31.
[15] Saxena M, Mutalik S, Reddy MS. Formulation and evaluation of transdermal patches of metoclopramide hydrochloride. Indian Drugs 2006; 43: 740-5.
[16] Panigrahi L, Ghosal SK. Formulation and evaluation of pseudolatex transdermal drug delivery system of terbutaline sulphate. Indian J Pharm Sci 2002; 64: 79-82.
[17] Sankar V, Johnson DB, Raghuraman S, Chandrasekaran AK. Design and evaluation of nifedipine transdermal patches. Indian J Pharm Sci 2003; 65: 510-5.
[18] Jayaprakash S, Sathish SK, Nagarajan M.Development and evaluation of risperidone membrane controlled transdermal therapeutic system. Indian Pharmacist 2007; 65: 64-6.
- Abstract Viewed: 456 times
- IJPS_Volume 6_Issue 3_Pages 163-170 Downloaded: 352 times